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MicroarrayNeonatal infection remains a primary cause of infantmorbidity andmortalityworldwide and yet our understand-
ing of how human neonates respond to infection remains incomplete. Changes in host gene expression in
response to infection may occur in any part of the body, with the continuous interaction between blood and
tissues allowing blood cells to act as biosensors for the changes. In this study we have used whole blood tran-
scriptome proﬁling to systematically identify signatures and the pathway biology underlying the pathogenesis
of neonatal infection. Blood samples were collected from neonates at the ﬁrst clinical signs of suspected sepsis
alongside agematched healthy control subjects. Herewe report a detailed description of the studydesign, includ-
ing clinical data collected, experimental methods used and data analysis workﬂows and which correspond with
data in Gene Expression Omnibus (GEO) data sets (GSE25504). Our data set has allowed identiﬁcation of a
patient invariant 52-gene classiﬁer that predicts bacterial infection with high accuracy and lays the foundation
for advancing diagnostic, prognostic and therapeutic strategies for neonatal sepsis.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).edicine, Edinburgh Infectious
K.
n), p.ghazal@ed.ac.uk
itute of Psychiatry and NIHR
th London and Maudsley NHS
d Evolution, King’s Buildings,
Australian Health and Medical
ia 5000, Australia.
h University, Commercial Road,
(continued)
Speciﬁcations
Sequencer or
array type
Illumina HT-12V3.0 Whole Human Genome microarray,
CodeLink 55K Whole Human Genome microarray, Affymetrix
U219 Whole Human Genome microarray and Affymetrix HG
U133 Plus 2.0 Whole Human Genome microarray
Data format Raw data (Tab delimited text ﬁles of background subtracted
signals and .CEL ﬁles)
Experimental
factors
Blood culture or cerebrospinal ﬂuid positive bacterial sepsis vs.
healthy control whole blood samples and culture negative
suspected infected samples
Experimental
features
A case–control gene expression proﬁling study of whole blood
taken from neonates at the ﬁrst clinical sign of sepsis and control
healthy neonates. Study includes training and replication sets for
blood culture positive samples and clinical evaluation set of blood
culture negative sepsis cases. Results compared blood culture or
cerebrospinal ﬂuid positive septic neonates, blood culture negative
septic neonates and healthy control neonates. Prior power
calculations were based on Healthy Edinburgh neonates using the
CodeLink platform and Gambian infants (9 months of age) were
used for further reﬁnement of power calculations using Illumina
HT-12 platform.
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
(continued)
Speciﬁcations
Consent Written informed consent was obtained from parents of all
enrolled infants in accordance with approval granted by the
Lothian Research Ethics Committee for blood samples for RNA
isolation obtained at the ﬁrst time of clinical signs of suspected
sepsis (reference 05/s1103/3). Samples obtained from The
Gambia conformed to MRC policy regarding ethical research in
children and were approved by the local scientiﬁc coordinating
committee (SCC), the Joint Gambia Government/MRC Ethics
Committee and by the London School of Hygiene and Tropical
Medicine Ethics Committee (reference SCC1085 Pilot Study 1
(L2008.63))
Sample source
location
Edinburgh, UK and The Gambia
42 P. Dickinson et al. / Genomics Data 3 (2015) 41–48Direct link to deposited data
Deposited data are available here: http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE25504.Experimental design, materials and methods
Patient demographics and experimental design
The study was conducted in the Neonatal Unit, Royal Inﬁrmary
of Edinburgh and the Division of Pathway Medicine, University of
Edinburgh. The patient demographics, microbial organisms isolated
and reasons for blood sampling in controls for all patient sets are
shown in Table 1. Infants having blood cultures taken to investigate
suspected infection (Table 1B) and “well” control infants having bloodTable 1
Patient demographics of samples used, microorganisms identiﬁed from infected patients and r
Patient demographics of samples used
Sample set Training set P
Infection status Infected
(n = 28)
Control
(n = 35)
In
(n
Male 15 (54%) 22 (63%) 1
Gestation completed at birth (week):
range (mean)
24–38 (28.5) 26–42 (37.9) 2
Gestation completed at sampling (week):
range (mean)
26–39 (31.1) 31–44 (39.4) 2
Birthweight (g): range (mean) 430–3380 (1126) 650–4570 (3080) 4
Microorganisms identiﬁed from infected patients Re
Organism Training set Platform test set Validation test set Re
Coagulase negative
staphylococcus
15 8 7 Scr
thy
Enterococcus species 4 3 1 Bili
Group B Streptococcus 2 2 1 “Ro
scr
Klebsiella species 2 1 2 Ele
der
Candida albicans and
Klebsiella species
1 1 – Scr
scr
Escherichia Coli 1 1 1 Blo
po
Enterobacter cloacae 1 1 – Scr
blo
Pseudomonas aeruginosa 1 1 1 Ne
CMV 1 – –
Listeria monocytogenes – – 1
Serratia marcescens – – 2
A. Patient demographics of samples used. Patient sample details are shown displaying the dem
Organisms detected for each infected infant are shown— these samples were taken at, orwithin
The reasons for clinical blood sampling in the control group are shown— all of the screening tes
et al. 2014 [2] by permission from Macmillan Publishers Ltd: Nature Communications [2], copytaken for other clinical reasons (Table 1C) were studied. Samples taken
from patients with suspected clinical infection that proved to have mi-
crobiological evidence of infection from a usually sterile body site were
identiﬁed and formed the infected group. Full clinical assessment for
early and late symptoms and signs of sepsis followed criteria for neona-
tal sepsis taken from data as detailed in Table 2, with the blood culture
test used as the ‘gold standard’ for diagnosis of sepsis. Five infants had
samples included from more than one episode of infection. To meet
with laboratory regulations, samples that could be considered ‘high
risk’were excluded. Infantswere not included in the study if themother
was known to be positive for hepatitis B, HIV or hepatitis C viruses. In
cases where the mother was known to have a history of drug misuse
andhad not had antenatal screening for blood-borne viruses, the infants
were also excluded. Other exclusion criteria were infants who did not
require clinical blood samples and infants for whom extra blood sam-
plingmight be of particular risk, for example, infantswith anunderlying
disorder causing anemia. Before embarking on this study we had previ-
ously performed a power calculation using the CodeLink chip platform
[1] on neonatal samples but we also performed a power calculation
using the Illumina chip platform, on an independent set of 30 infant
samples at 9 months of age, before vaccination. This showed that the
study design has 90% power to detect a twofold change in expression
with an a of 1% (false discovery rate (FDR) corrected), for more than
99% of 35,177 gene probes present on the array [2]. A schematic of
patient recruitment and sample processing workﬂow for the samples
processed for the training, replication and validation arm of the study
is shown in Fig. 1.
Sample collection and RNA extraction
For RNA isolation, blood (500 μl–1 ml) was immediately injected
into PAXgeneTM blood RNA tubes (PreAnalytiX BD/QIAgen) and mixedeasons for blood sampling in controls.
latform test set Validation test set
fected
= 18)
Control
(n = 24)
Infected
(n = 16)
Control
(n = 10)
0 (56%) 15 (63%) 10 (63%) 9 (90%)
4–38 (28.8) 26–42 (37.3) 23–40 (28.3) 24–41 (31)
6–39 (30.8) 31–44 (39.1) 25–41 (33.8) 29–42 (34.9)
30–3380 (1236) 650–4350 (2941) 635–3160 (1134) 800–4220 (1932)
asons for blood sampling in controls
ason Training set Platform test set Validation test set
eening test: maternal
roid disease
17 9 –
rubin check due to jaundice 5 4 1
utine” neonatal
eening (preterms)
5 4 6
ctrolyte check: previous
anged Na
3 3 –
eening test: pigmented
otum
2 1 3
od count check: Coomb's
sitive
1 1 –
eening test: newborn
odspot
1 1 –
onatal encephalopathy 1 1 –
ographics of the population studied. B. Microorganisms identiﬁed from infected patients.
6 h of, the time of clinical suspicion of infection. C. Reasons for blood sampling in controls.
ts in these infants were normal. Table 1 was adapted from Supplementary Table 3 of Smith
right (2014).
Table 2
Clinical details of patient samples used in the study. Table 2 was adapted from Supplementary Data 4 of Smith et al. 2014 [2] by permission fromMacmillan Publishers Ltd: Nature Com-
munications [2], copyright (2014).
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Inf009 Illumina Infected 28 33 720 Girl caucasian Coagulase negative staphylococcus Blood late 0 14
Inf012 CodeLink, AffyU133 Infected 34 6 2150 Girl caucasian Enterovirus Csf late 0 10
Inf032 CodeLink, AffyU133 Infected 40 8 3180 Girl caucasian Listeria monocytogenes Csf late 0 14
Inf047 Illumina, CodeLink Infected 29 12 1380 Boy caucasian Candida Blood Also Klebsiella in peritoneal fluid late 0 7
Inf075 Illumina, CodeLink Infected 70 26 74 890 Girl caucasian Cytomegalovirus Blood, urine late 0 3
Inf082 Illumina, CodeLink Infected 29 8 1230 Boy caucasian Enterobacter cloacae late 0 14
Inf083 Illumina, CodeLink Infected 29 36 1405 Girl not stated Enterococcus faecium Blood late 0 10
Inf084 Illumina, CodeLink Infected 116 28 10 720 Boy caucasian Coagulase negative staphylococcus Blood 2 cultures late 0 14
Inf089 Illumina, CodeLink Infected 27 9 850 Boy not stated Coagulase negative staphylococcus Blood late 0 3
Inf091 Illumina, CodeLink Infected 38 1 3900 Girl caucasian Group B streptococcus Blood early 0 5
Inf102 Illumina, CodeLink Infected 103 27 31 785 Girl not stated Pseudomonas aeuruginosa Blood late 0 14
Inf107 CodeLink Infected 108,110 23 8 655 Boy not stated Coagulase negative staphylococcus Blood 2 cultures late 0 7
Inf111 Illumina Infected 115 28 14 1200 boy caucasian Coagulase negative staphylococcus 2 cultures late 0 9
Inf112 Illumina, CodeLink Infected 124,129,130 24 10 660 Girl Oriental Group B streptococcus Blood late 0 11
Inf114 Illumina, CodeLink Infected 99 26 9 955 Girl caucasian Coagulase negative staphylococcus Blood late 0 11
Inf116 Illumina Infected* 84 28 14 720 boy caucasian Coagulase negative staphylococcus Abscess Blood culture next day positive for coagulase negative staphlococcus late 0 14
Inf118 CodeLink Infected 120,122 29 59 940 Boy caucasian Coagulase negative staphylococcus Blood late 0 10
Inf119 Illumina Infected 125 28 16 983 girl not stated Coagulase negative staphylococcus Blood late 0 18
Inf125 Illumina, CodeLink Infected 119 28 12 983 Girl not stated Coagulase negative staphylococcus Blood late 0 18
Inf132 Illumina, CodeLink Infected 131,145 27 16 1100 Boy not stated Enterococcus faecalis Blood late 0 21
Inf133 Illumina Infected 27 4 1140 boy not stated Coagulase negative staphylococcus Blood late 0 5
Inf137 CodeLink Infected 29 43 1150 Boy caucasian Coagulase negative staphylococcus Blood late 0 18
Inf138 Illumina, CodeLink Infected 25 16 870 Girl caucasian Coagulase negative staphylococcus Blood late 0 10
Inf145 Illumina Infected 131,132 27 12 1100 boy not stated Enterococcus faecalis Blood late 0 21
Inf149 Illumina Infected 148, 151, 155 27 15 840 girl caucasian Klebsiella Csf late 0 25
Inf152 Illumina, CodeLink Infected 28 21 450 Boy caucasian Coagulase negative staphylococcus Blood late 0 15
Inf155 CodeLink Infected 148,149,151 27 10 840 Girl caucasian Klebsiella pneumoniae Blood late 0 25
Inf157 Illumina Infected 158,164,167 28 24 820 girl caucasian Coagulase negative staphylococcus Blood late 8 16
Inf159 Illumina, CodeLink Infected 30 9 1335 Boy caucasian Enterococcus  Blood late 0 11
Inf161 CodeLink Infected 28 9 1090 Boy caucasian Klebsiella oxytoca Blood and csf late 0 23
Inf162 Illumina, CodeLink Infected 156 27 6 1130 Boy asian Coagulase negative staphylococcus Blood 2 cultures late 0 5
Inf164 Illumina, CodeLink Infected 157,158,167 28 26 820 Girl caucasian Klebsiella oxytoca Blood late 0 16
Inf191 Illumina, CodeLink Infected 37 0 2970 Boy caucasian Escherichia coli BloOd early 0 7
Inf198 Illumina, CodeLink Infected 175,185,203 32 8 1070 Boy caucasian Coagulase negative staphylococcus Blood late 0 10
Inf203 Illumina Infected 175,185,198 32 35 1070 boy caucasian Coagulase negative staphylococcus Blood late 0 6
Inf216 AffyU219 Infected 25 66 810 girl not stated Enterococcus Blood late 0 16
Inf226 AffyU219 Infected 29 29 1385 boy not stated Enterococcus Blood late 0 7
Inf239 AffyU219 Infected 27 5 680 boy not stated Pseudomonas aeuruginosa Blood late 0 2 days (until death)
Inf262 AffyU219 Infected 24 111 690 girl caucasian Group B streptococcus Blood late 0 13
Inf271 AffyU219 Infected 267 29 48 1040 boy not stated Coagulase negative staphylococcus Blood Klebsiella 4 days previously in blood, candida 2 days later late 0 10
Inf275 AffyU219 Infected 28 77 1255 boy not stated Coagulase negative staphylococcus Blood late 0 7
Inf287 AffyU219 Infected 26 62 880 girl not stated Escherichia coli Blood late 0 13
Inf297 AffyU219 Infected 283, 286, 299 30 39 1490 boy not stated Serratia marcescens Blood late 0 13
Inf299 AffyU219 Infected 283, 296, 297 30 44 1490 boy not stated Serratia marcescens Blood late 0 13
NEC253 AffyU219 Infected 30 44 1390 girl not stated Coagulase negative staphylococcus Blood late 13 10
NEC283 AffyU219 Infected 297, 299, 286 30 12 1490 boy not stated Candida Peritoneal fluid Enterobacter blood 3 days earlier late 11 hours post op 11
Sus002 CodeLink Possible 41 1 3480 Girl asian 0 3
Sus005 CodeLink Possible 25 68 750 Boy caucasian 0 2
Sus008 CodeLink Possible 33 0 1370 Girl caucasian 0 5
Sus010 CodeLink Possible 38 0 3660 Boy caucasian 0 5
Sus011 CodeLink Possible 35 0 2510 Girl caucasian 0 5
Sus013 CodeLink Possible 40 0 3530 Boy Mixed 0 2
Sus019 CodeLink Possible 29 0 1510 Girl Caucasian 0 3
Sus020 CodeLink Possible 34 0 1930 Girl Caucasian 0 3
Sus024 CodeLink Possible 34 0 2170 Boy Caucasian 0 2
Sus025 CodeLink Possible 34 0 2210 Boy Caucasian 0 2
Sus026 CodeLink Possible 35 0 2725 Boy Caucasian 0 5
Sus027 CodeLink Possible 41 0 3615 Boy Asian 0 5
Sus033 CodeLink Possible 35 0 1840 Boy Caucasian 0 5
Sus034 CodeLink Possible 29 0 1490 Girl Caucasian 0 5
Sus035 CodeLink Possible 41 1 4860 Boy Caucasian 0 4
Sus036 CodeLink Possible 41 0 3360 Girl Caucasian 0 0
Sus037 CodeLink Possible 26 32 700 Boy Caucasian 0 0
Sus038 CodeLink Possible 29 0 1130 Boy Caucasian 0 0
Sus039 CodeLink Possible 29 0 1345 Boy Caucasian 0 0
Sus041 CodeLink Possible 29 4 1750 Boy Caucasian 0 2
Sus044 CodeLink Possible 36 0 2550 Boy Caucasian 0 2
Sus053 CodeLink Possible 35 0 2230 Girl Hispanic 0 5
Sus054 CodeLink Possible 37 0 3080 Girl Caucasian 0 2
Sus055 CodeLink Possible 41 1 4520 Girl Caucasian 0 5
Sus057 CodeLink Possible 37 0 2985 Girl Afrocaribbean 0 2
Sus059 CodeLink Possible 41 1 3600 Boy Not stated 12 hours after 5
Sus061 CodeLink Possible 30 9 1210 Girl Not stated 0 10
Sus064 CodeLink Possible 26 4 970 Girl Not stated 0 12
Sus068 CodeLink Possible 40 1 3680 Boy Not stated 0 0
Sus074 CodeLink Possible 34 0 2220 Girl Not stated 0 5
Vir228 AffyU219 Infected 31 24 1920 Boy Not stated Rhinovirus Nasopharyngeal secretions late n/a n/a
Vir269 AffyU219 Infected 35 5 1290 boy Not stated Cytomegalovirus Blood, urine late 4 days 16 days antiviral therapy
Vir278 AffyU219 Infected 279 24 58 855 boy Not stated Rhinovirus Nasopharyngeal secretions late 0 0
(continued on next page)
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X X 0 0 X 0 X 0 0 0 0 Neutrophilia, low platelets 0 115 16.4 15.03 14 7.29 3.7
X 0 0 X X 0 0 0 X X X 0 Low platelets 0 184 18.1 5.44 7 7.26 3.44
0 0 0 0 X 0 0 X X X 0 Red groin Elevated white cell count 0 168 29.4 23.81 320 7.40 5.9
X 0 0 0 X 0 X 0 0 0 X Known NEC, central line Low platelets X 7 91 9.9 6.34 53 7.28 4.2
0 X X 0 0 0 0 0 0 0 X 0 81 5.8 1.18 250
0 X X 0 X 0 0 0 0 0 0 Quiet, intubated the next day Low platelets 0 143 16.2 12.01 0
0 X X 0 0 0 0 0 0 0 0 Low platelets 0 89 9.8 3.6 31
0 0 X 0 X 0 0 0 X 0 0 Low platelets 0 98 13.7 4.8 40 2.36
0 X X X X 0 X 0 X X 0 Loose stool Neutrophilia 0 83 23.9 20.08 453 7.24 6.3
0 0 0 0 X 0 X X 0 0 X Quiet 0 173 10 7.8 200 7.38 3.87
0 0 0 0 0 X X 0 X 0 0 Central line, blood sugar instability Low platelets X >30 122 6.9 3.86 N/A 7.20 2.3
0 0 0 X 0 0 X 0 0 0 0 Hyperglycaemia Low platelets, high white cell count X 7 118 31 24 88 7.14 10.4
0 X X X 0 0 X 0 X 0 X Neutrophilia 0 112 24 22 205 7.22 5.7
0 X X 0 X 0 X 0 X X X Hyperglycaemia High white cell count, neutrophilia 0 109 49.7 44.7 317 7.18 14.9
0 0 X 0 0 0 0 0 X 0 X 0 130 13 6 287 7.25 8.46
0 0 0 0 0 0 X 0 0 0 0 Red hot fluctuant swelling forearm Low platelets 0 111 15.1 6.8 101
X X X 0 0 0 0 0 X 0 X Low platelets 0 88 3.1 2 108 7.26
0 X X 0 X 0 X 0 X 0 X Low platelets 0 109 17.1 4.8 78 7.20 3.33
0 X X 0 0 0 X 0 X 0 X High white cell count  0 85 14.1 10.86 324 7.29 3.82
0 X X 0 0 0 X 0 0 0 0 Low platelets 0 94 14 7.4 60
0 X X 0 0 0 0 0 0 X 0 Hyperglycaemia 0 138 7.5 6.6 241 7.26 9.9
0 X X X X 0 X 0 X 0 X Low platelets 0 126 16.4 13.6 79
0 X X 0 X 0 0 0 X 0 0 Quiet 0 108 13.9 8.3 177 7.37 10.4
X X X 0 0 0 X 0 X 0 0 Low platelets 0 131 6.3 3.8 66
0 X X X X 0 X 0 X 0 X Quiet Low platelets 0 116 7.6 3.2 10 7.22 2.4
0 X 0 X 0 0 0 0 0 0 0 Trisomy 21 Low platelets, hypoglycaemia X 12 158 18.3 13.4 92 7.19 2
X X X 0 0 0 X 0 X 0 0 0 143 9 5.2 224 7.28 5.1
0 0 0 0 0 0 X 0 X 0 0 Surgical wound abscess/granuloma, central line Low platelets 0 148 5.6 2.2 104 7.37
X 0 X 0 X 0 0 0 0 X 0 Elevated white cell count, bordeline platelets 0 171 22.7 17.3 142 7.29
X X X 0 0 0 X 0 X X X Low platelets 0 117 7 2.7 47 7.19 6.8
0 X X 0 X 0 0 0 X 0 0 0 103 11.1 7.5 237 7.25 11
X X X X X 0 0 0 X 0 0 Quiet, previous nec Low platelets 0 127 10.9 9.2 84 7.21
X 0 0 0 0 0 0 0 X 0 0 Neutrophilia 0 189 16 14.12 223 7.39 6.3
X X X X X 0 0 0 X 0 X Quiet, tachycardic 0 116 6.8 4.73 287 7.2 4.5
X X X X X 0 0 0 X 0 X Quiet Low platelets 0 124 7.4 3.94 67 7.38 3.8
0 X 0 0 0 0 X 0 0 0 0 Glucose instability Low platelets 0 131 11.8 5.23 15 7.39 3.1
0 X 0 X X 0 0 0 0 0 0 Central line 0
0 X 0 0 0 0 X 0 0 0 X Central line Low platelets X 2 94 11.7 5.5 33 11.5
X X 0 X X X 0 0 0 0 0 Raised lactate, stoma Bordeline platelets 0 114 6.6 3.8 125 7.18 5.4
0 X 0 0 0 0 0 0 0 0 0 Extravasation Low platelets 0 113 10 3.4 85 7.38 4.2
0 0 0 0 X 0 0 0 X 0 0 Central line, previous NEC 0 102 19 13.66 196
0 X 0 X X 0 X X 0 0 X 0 110 7.9 3.9 231 7.38 4.7
0 X X X X 0 0 0 0 0 0 Low white cells, low platelets 0 110 2.7 1.6 104 7.31
0 X X X X 0 X 0 X 0 X Central line, blood sugar instability Low platelets 0 85 2.8 1.8 55 7.23 4.8
0 0 0 0 0 0 X 0 0 0 0 Rash, sore Neutrophilia 0 127 27.5 21.1 339 Necrotising enterocolitis
0 0 0 0 0 0 0 0 0 0 0 <12 hours post-op NEC Low platelets 0 165 16.1 12.2 62 7.43 4 Post-op for necrotising enterocolitis
0 0 0 0 X 0 0 X 0 0 0 Rash 0 156 15.9 11.28 248 7.43 Low
X X X 0 0 0 0 0 0 0 X Rash, oedema 0 105 6.2 2.7 190 7.25 5.7 High Patent ductus arteriosus ligated 4 days later
X X 0 0 0 0 0 0 0 0 0 IUGR 0 193 10.4 3.49 208 Medium
X X X 0 0 0 0 X X 0 X 0 164 14.3 9.91 199 7.26 4.7 High
X 0 0 X 0 0 0 X 0 0 0 Sticky eye Neutrophilia 0 174 29.6 23.29 200 7.26 2 Medium
X 0 0 0 0 0 0 X 0 0 0 0 181 17.2 9.59 244 7.34 2.3 Low
0 0 0 0 0 0 0 0 0 0 0 0 174 15.7 8.16 241 7.27 1.9 Low
0 0 0 0 0 0 0 X 0 0 0 No respiratory effort at birth 0 188 6 2.78 243 7.36 1.47 Low
X 0 0 0 0 0 0 0 0 0 0 0 186 11.1 2.92 274 7.31 3.64 Low
X 0 0 0 0 0 0 0 0 0 0 Rash 0 183 12.5 5.08 282 7.22 Low
X X 0 0 0 0 0 0 0 0 0 Rash 0 163 14.2 7.83 246 7.12 2.1 Medium
0 0 0 0 0 0 0 X X 0 0 Poor suck 0 184 21.8 11.99 306 7.19 3.3 Medium
X 0 0 0 0 0 0 0 0 0 0 Rash 0 162 11.5 10.22 278 7.27 3.5 Medium
X 0 0 0 0 0 0 0 0 0 0 0 210 9.3 9.3 241 7.27 0.3 Medium
X 0 0 0 0 0 0 X 0 0 0 0 196 20.1 12.66 293 Low
0 0 0 0 X 0 0 0 X 0 0 0 185 20 13.53 208 3.9 Low
X X X 0 0 0 0 0 0 0 X Quiet 0 96 8.6 2.06 171 7.26 4.2 Low
0 0 0 0 0 0 0 0 0 0 0 Plethoric Neutropenia 0 182 6.2 0.97 202 7.35 Low
0 0 0 0 0 0 0 0 0 0 0 Plethoric Neutropenia 0 195 5.4 1.43 214 7.34 1.6 Low
0 0 0 0 0 0 0 0 0 0 X Hypertension, 2 days post op diaphragmatic hernia 
i
0 119 10.6 6.7 198 7.19 4.4 Medium Post-op diaphragmatic hernia
X 0 0 0 0 0 0 0 0 0 0 Hypoglycaemia 0 179 10 2.62 286 1.17 Low
X X 0 0 X 0 0 0 X 0 X 0 147 6.4 3.72 261 7.16 5.2 High
X 0 0 0 X 0 0 0 0 0 0 Poor feeding 0 173 21.6 16.2 259 7.31 4.4 Medium
X 0 0 0 0 0 0 0 0 0 0 Rash 0 231 7.7 5.11 164 7.39 3 Low
X 0 0 0 0 0 0 0 0 0 0 Starry eyed 0 201 18.4 11.91 189 7.35 3.6 Low
X 0 0 0 0 0 X 0 X X 0 Pale, fine creps in chest, spleen tipable Neutrophilia 0 201 21.6 17.05 310 High
0 0 0 0 X 0 X 0 0 0 0 ?NEC, quiet High white counr, neutrophilia 0 155 42.4 36.46 392 7.37 4.3 High
0 X X 0 0 0 0 0 X 0 0 Pale Neutrophilia 0 112 29 20.33 288 7.09 6.5 High
0 0 0 0 X 0 0 0 0 0 0 Offensive liquor 0 179 10.9 4.78 235 Low
X 0 0 0 0 0 0 0 0 0 0 0 182 16.5 9.05 337 7.19 2 Medium
0 0 0 0 0 0 0 0 0 0 0 0 86 8.5 2.7 410 7.36 3.9
0 0 0 0 0 0 0 0 0 X 0 Rash, IUGR, brain cyst, splenomegally Low platelets 0 179 4.9 2.21 33 3.3
0 0 0 0 X 0 0 0 0 0 0 Tachycardic, nasal secretions 0 98 10.7 2.5 472 7.34 5.4
Table 2 (continued)
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45P. Dickinson et al. / Genomics Data 3 (2015) 41–48by inversion. Samples were then frozen at−20 °C until RNA extraction
occurred as described previously [1]. RNA was quantiﬁed and A260:A280
ratios generated using a ThermoSpectronic NanoDropTM1000 spectro-
photometer. RNA quality was assessed qualitatively by examining the
electropherogram and quantitatively from the RNA integrity number
(RIN) generated by an Agilent 2100 Bioanalyser.
Gene expression proﬁling using microarrays
Microarray study design
This study was designed as a prospective case–control study to
biologically and computationally infer a set of genes acting as a reliable
classiﬁer for bacterial sepsis in neonates. This design entails a main data
set to identify genes and train a classiﬁcation algorithmand is referred to
as ‘training set’. Subsequent validation of the trained classiﬁer requires
independent data sets referred to as ‘test sets’ (distinctions between
them outlined below). Based on earlier power calculations, the training
set (Illumina HT-12 v3 platform) was established with 27 patient
samples with a conﬁrmed blood culture-positive test for sepsis (bacte-
rial infected cases) and 35 age-matched controls (it also contains one
cytomegalovirus-infected case that was not used for classiﬁcation),
all sub-selected by sample quality from the full study population. For
assessing reproducibility of our gene classiﬁer with a different assay
platform, we examined a subset of 42 of these samples using theFig. 1. Study recruitment and sample processing. This ﬂow diagram depicts process of neona
arrows are color-coded as follows.Healthy (presenting for clinical reasons other than suspected
infections = gray; neonate samples with blood-culture test conﬁrmed infection = pink; neona
Figure 1 was adapted from Supplementary Figure 9 of Smith et al. 2014 [2] by permission fromCodeLink gene expression platform (comprising 18 bacterial infected
and 24 control samples) named in this study as ‘platform test set’. Sub-
sequently, for independent clinical evaluation, the 52-gene set classiﬁer
was applied to a further 29 new and independent samples (comprising
16 bacterial infected, 3 viral infected and 10 control samples) named
in this study as ‘validation test set’ which were analyzed using the
CodeLink, Affymetrix HG-U133 Plus 2.0 and Affymetrix U219 gene
expression platforms. The classiﬁer was then used on 30 suspected
infected samples and classiﬁcation of samples into infected and non-
infected cases compared against an ‘expert’ clinical classiﬁcation.RNA labeling and hybridization
For Illumina HT-12 v3 arrays total RNA was converted to double-
stranded cDNA, followed by an in vitro transcription ampliﬁcation
step to generate labeled cRNA, using the Ambion Illumina TotalPrep-
96 RNA Ampliﬁcation Kit. The cRNA was quantiﬁed by A260 measure-
ment using a NanoDropTM1000 spectrophotometer. The cRNA was
normalized and hybridized onto the Illumina HT-12 v3 arrays overnight
(16 h) at 58 °C. The unhybridized and non-speciﬁcally hybridized cRNA
was washed away. The arrays are stained with Cy3-Streptavidin to
bind to the analytical probes that have hybridized to the array. Arrays
were scanned using an Illumina IScan scanner and ﬂuorescence emis-
sions were recorded in high-resolution images. The intensities of thetal subject recruitment over sample processing and microarray hybridization. Boxes and
infection) control neonate samples=blue; neonate samples of suspected but unconﬁrmed
te samples with blood-culture negative test but conﬁrmed viral infection = striped pink.
Macmillan Publishers Ltd: Nature Communications [2], copyright (2014).
Fig. 2. Sequence of study analyses prior to validating 52-gene set as a classiﬁer. This ﬂow diagram identiﬁes the sequence of analyses carried out on Illuminamicroarray data. The gray box
indicates that the analyses within are used in combination to inform a subsequent result. Figure 2 was adapted from Supplementary Figure 10 of Smith et al. 2014 [2] by permission from
Macmillan Publishers Ltd: Nature Communications [2], copyright (2014).
46 P. Dickinson et al. / Genomics Data 3 (2015) 41–48images were extracted using GenomeStudio (2010.3) Gene Expression
Module(1.8.0) software.
For CodeLink arrays the biotin-labeled cRNA target is prepared by
a linear ampliﬁcation method using tailed oligo dT priming of total
RNA. After second-strand cDNA synthesis, the cDNA undergoes an
in vitro transcription (IVT) reaction to produce the target cRNA. Var-
ious quality control procedures are incorporated. Hybridization is
performed overnight and post-hybridization processing includes a
stringent wash to remove unbound and non-speciﬁcally hybridized
target molecules and staining with CyTM5-streptavidin conjugate.
Several non-stringent washes remove unbound conjugate. The
bioarrays are then dried and scanned on the Agilent G2567A scanner
at 5 nm resolution. Raw data were obtained from the scanned images
using CodeLinkTM EXPv4.1 (GE Healthcare) feature extraction
software.
For Affymetrix HG-U133 plus 2.0 arrays biotin labeled cRNA tar-
get is prepared by a linear ampliﬁcation method following reverse
transcription of total RNA into T7 tailed double stranded cDNA. Bio-
tinylated target cRNA was puriﬁed using RNeasy columns according
to the manufacturer's instructions (QIAgen Ltd., Crawley, UK) and
quantiﬁed by spectrophotometry. Fifteen micrograms of puriﬁed bi-
otinylated cRNAwas fragmented by heating for 35min at 94 °C in thepresence of magnesium ions, spiked with eukaryotic hybridization
control and hybridized to HG-U133 plus 2.0 microarrays overnight
at 45 °C. After hybridization the arrays were washed, stained with
phycoerythrin coupled streptavidin and processed on the Affymetrix
GeneChip Fluidics Workstation 400 using the EukGE-Ws2v4 proto-
col. Microarrays were then scanned using the Affymetrix GeneChip
Scanner 3000 using GeneChip Operating Software instrument con-
trol and data acquisition system.
For Affymetrix U219 arrays total RNA was reverse transcribed to
synthesize ﬁrst-strand cDNA. This cDNA was then converted into a
double-stranded DNA template for in vitro transcription to synthesize
cRNA incorporating a biotin-conjugated nucleotide. This cRNA was
then puriﬁed to remove unincorporated NTPs, salts, enzymes, and inor-
ganic phosphate. The biotin-labeled cRNA was then fragmented and
prepared for hybridization using the GeneChip HT Hybridization,
Wash and Stain Kit for GeneTian (Affymetrix). Arrays were then proc-
essed and scanned on the Affymetrix GeneTitan Instrument as detailed
in the Affymetrix GeneChip Command Console 2.0 User Guide.
Data normalization and analysis
For the computational and statistical pathway biology aspects of this
study, a summary of the data analysis workﬂow is shown in Fig. 2. The
Fig. 3. Training and testing of 52-gene classiﬁer of sepsis in neonates. This diagram details the stages comprising training and testing of the ROC-based classiﬁer. Top box represents pro-
cesses in the training of the classiﬁer; bottombox represents processes in the testing of the classiﬁer on various types of test sets. LOOCV stands for leave-one-out-cross-validation,which is
the iterative process in which a single sample of the training set is predicted based on the classiﬁer trained on all remaining samples. Black arrows are data processing steps; red arrows
indicate classiﬁer training and prediction steps. Sample color coding: healthy (presenting for other clinical reasons than suspected infection) control neonate samples = blue; neonate
samples of suspected but unconﬁrmed infections = gray; neonate samples with blood-culture test conﬁrmed infection = pink; neonate samples with blood-culture negative test but
conﬁrmed viral infection = striped pink. Figure 3 was adapted from Supplementary Figure 11 of Smith et al. 2014 [2] by permission fromMacmillan Publishers Ltd: Nature Communica-
tions [2], copyright (2014).
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statistical analysis, gene feature selection and classiﬁer testing and
validation.
Data quality control: High-quality RNA (RNA integrity number
(RIN) greater than 7) from infected and control infants were hybridized
onto Illumina Human Whole-Genome Expression BeadChip HT-12 v3
microarrays comprising 48,802 features (human gene probes). Gene
expression levels, distributions and controls were assessed using the
arrayQualityMetrics package in Bioconductor [3]. A gender check was
performed using Y-chromosome-speciﬁc loci.
Processing: Using the ‘lumi’ Bioconductor package, raw data from
63 samples were transformed using a variance stabilizing transforma-
tion before robust spline normalization to remove systematic between-
sample variation. Microarray features that were not detected (using
function ‘detectionCall’) on any of the arrayswere removed fromanalysis
and the remaining 23,342 features were used for subsequent statistical
analysis.
Statistical analysis: Data were statistically examined to assess gesta-
tional age as a confounding factor. Within each sample group (control,
infected), samples were age classiﬁed into bins based on the 33% and
66% corrected gestational age quantile values, yielding three age group-
ings. Per-gene hypotheses of differential expression between bacterial
infection cases and control neonates were tested through linear model-
ing of the log2 scale expression values between groups and subsequentempirical Bayesian approaches to moderate the test statistic by pooling
variance information from multiple genes (Bioconductor package
‘limma’ [4]). This included vertical p-value adjustment for multiple test-
ing (Benjamini–Hochberg) to control for false discovery rate at a 1% level.
Gene feature selection for classiﬁer: Computational network-based ap-
proaches were used to examine relationships in the data using correlation
of gene expression and biological relationships. Statistically signiﬁcant dif-
ferentially expressed genes were examined further: heat maps and line
graphs with hierarchical clustering by Euclidean distance were examined
using Partek Genomics Suite v6.5, and visualization of networks of genes
looking for patient-speciﬁc responses using BioLayout Express 3D [5].
These analyses were carried out step-wise using a pathway-biology ap-
proach, becoming more focused until a deﬁned sub-network of 52 differ-
entially expressed genes was identiﬁed [2]. The selected genes had
adjustedpvalues of≤10−5, fold changesof≥4andwerehighly connected
in terms of biological pathways and networks.
Classiﬁer training and testing: First, a simulation model based on
these 52 genes was established to assess the relationship between the
number of gene predictors and classiﬁcation error and establish suit-
ability of this gene set for use with a panel of classiﬁer algorithms.
This approach used leave-one-out cross-validation with four different
machine learning methods: Random Forests, Support Vector Machines,
K Nearest Neighbour, and ROC-based [6-9] (Fig. 3). Leave-one-out cross
validation was repeated 100 times for each set of selected genes
48 P. Dickinson et al. / Genomics Data 3 (2015) 41–48following a random ordering of the data at each replication tominimize
variability of the error estimates [10].
Next, the ROC-based classiﬁcationmethod [9], (that does not require
tuning of parameters and simpliﬁes classiﬁcation to a univariate deci-
sion that can easily be applied to independent data) was trained on
the training set to learn the gene expression level differences that distin-
guish between controls and cases of infection. Internal accuracy of
this classiﬁer was tested through leave-one-out cross-validation on
the training set, prior to its testing on independent data. Using the
platform test set, a subset of 42 of the training set samples (18 infected,
24 controls) hybridized to CodeLink™Whole Human Genome arrays,
the trained ROC classiﬁer was tested for platform-dependent perfor-
mance. Subsequently, the classiﬁer was tested for performance on
completely new and independent neonatal samples, consisting of a
further 26 samples (16 bacterially infected samples from 15 infants
and ten control samples)whichwere run onCodeLink™ (seven infected,
three control), Affymetrix® HG-U133 Plus 2.0 (two infected, three con-
trol) or Affymetrix® Human Genome U219 (nine infected, six control)
arrays. Finally, the classiﬁer was tested on n = 30 (hybridized to
CodeLink arrays) new and independent cases where infection was
suspected but not conﬁrmed through blood culture and performance
was compared against ‘expert’ clinical assessment (Table 2).
Discussion
We describe in this paper our detailed technical and analysis meth-
odology for our data set describing the host response to neonatal infec-
tion. This data set is a unique repository of data describing the host
response at the ﬁrst sign of neonatal infection and has allowed identiﬁ-
cation of a 52-gene classiﬁer that predicts bacterial infection with high
accuracy. This data set lays the foundation for advancing diagnostic,
prognostic and therapeutic strategies for neonatal sepsis and we hope
will be of great value for future further investigations by the wider
research community.
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